Kinetic analyses for species differences in P-glycoprotein-mediated drug transport

Journal of Pharmaceutical Sciences

Volumn 95, Issue 12, 2006, Pages 2673-2683

  Katoh, Miki ^a   Suzuyama, Naoto ^a   Takeuchi, Toshiyuki ^b   Yoshitomi, Sumie ^b   Asahi, Satoru ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Drug transport; In vitro models; Kinetics; Multidrug resistance transporters; P glycoprotein; Species differences

Indexed keywords

COMPLEMENTARY DNA; CYCLOSPORIN A; DEXAMETHASONE; DILTIAZEM; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG TRANSPORT; GENETIC TRANSFECTION; IMMUNOBLOTTING; MONKEY; NONHUMAN; PROTEIN EXPRESSION; SPECIES DIFFERENCE; TRANSCYTOSIS;

EID: 33846261622     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20686     Document Type: Article

References (25)

1. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
2. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Clin Invest 96:1698-1705.
3. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
4. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH. 2001. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 296: 723-735.
6. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P. 1995. Human (MDR1) and mouse (mdr1, mdr3) P-glycoprotein can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34: 32-39.
7. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 42:59-98.
8. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668.
9. 1. Pharm Res (in press).
10. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
11. Katoh M, Nakajima M, Yamazaki H, Yokoi T. 2000. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4. Pharm Res 17:1189-1197.
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
13. Hochman JH, Yamazaki M, Ohe T, Lin JH. 2002. Evaluation of drug interactions with P-glycoprotein in drug discovery: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 3:257-273.
14. Chen C, Liu X, Smith BJ. 2003. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4:272-291.
15. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
16. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. 1993. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077-6080.
17. Georges E, Bradley G, Gariepy J, Ling V. 1990. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87:152-156.
18. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quantitative evaluation of the function of small intestinal P-glycoprotein: Comparative studies between in situ and in vitro. Pharm Res 20:1163-1169.
19. Chiou WL, Jeong HY, Chung SM, Wu TC. 2000. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135-140.
20. He YL, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, Eastmond R, Rowland M. 1998. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 87:626-633.
21. Chiou WL, Buehler PW. 2002. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 19:868-874.
22. Yang CP, Cohen D, Greenberger LM, Hsu SI, Horwitz SB. 1990. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 265:10282-10288.
23. Yamamoto C, Murakami H, Koyabu N, Takanaga H, Matsuo H, Uchiumi T, Kuwano M, Naito M, Tsuruo T, Ohtani H, Sawada Y. 2002. Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol 54:1055-1063.
24. Molden E, Christensen H, Sund RB. 2000. Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. Drug Metab Dispos 28:107-109.
25. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33:587-595.